Avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA kinases, is an approved agent for the treatment of GIST, given that up to 85% of patients present mutations in either the PDGFRA or KIT genes [36]. Here, KIT is linked to gastrointestinal stromal tumor.